7.840

-0.300 (-3.69%)
Range 7.770 - 8.286   (6.64%)
Open 8.200
Previous Close 8.140
Buy Price 7.770
Buy Volume 11
Sell Price 7.850
Sell Volume 31
Volume 2,236,726
Value -
Remark
Measurement Type Value
EPS (USD) -0.132
Trailing EPS (USD) 0.297
NAV (USD) 6.997
Cash In Hand (USD) 10.104
Dividend -
Dividend Yield (%) -
PE -
Trailing PE 27.371
Price / NAV 1.163
Price / Cash In Hand 0.806
Issued & Paid-up Shares 83,102,700
Treasury Shares -
Market Cap (M) 676.456
Par Value (USD) n.a.
Beta - 75 Days -0.828
R-Squared - 75 Days(%) 0.36
Beta - 500 Days -18.003
R-Squared - 500 Days(%) 1.23
ISIN Code
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 30 Nov 2021 05:00.
Data powered by
View All Events

About ATEA PHARMACEUTICALS INC

Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals Inc., is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options. Its product candidates include vapendavir, which is an oral treatment for human rhinovirus (HRV) infections in moderate-to-severe asthmatics that is being evaluated in its Phase IIb SPIRITUS trial; BTA074, a Phase II topical antiviral treatment for genital warts caused by human papillomavirus (HPV) types 6 and 11; BTA585, an oral fusion (F) protein inhibitor in Phase IIa development for the treatment and prevention of respiratory syncytial virus (RSV)-A and RSV-B infections, and laninamivir octanoate in Phase II development for the treatment of influenza A and B infections. It also has preclinical RSV non-fusion inhibitor program.

Loading Chart...